- American City Business Journals•1 hour ago
Shares of Burlington biotech Flexion Therapeutics soared to their highest point in more than a year and a half on Thursday following an unconfirmed report that French drug giant Sanofi is in talks to acquire the company for more than $1 billion. FiercePharma, citing an unnamed source, reported Thursday morning that the board of Flexion (FLXN) has voted to accept a non-binding offer from Sanofi (SNY), the parent company of Cambridge-based Sanofi-Genzyme. A Flexion spokesman declined comment, adding that the biotech will continue to pursue an “independent” strategy with its lead product, Zilretta, a long-acting steroid injection for osteoarthritis of the knee that could compete with one of Sanofi’s own treatments, Synvisc.
- TheStreet.com•2 hours ago
Flexion is an arthritis-focused biotech company.
- Reuters•6 hours ago
Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival. Given earlier impressive clinical trial results, investors expect the Food and Drug Administration (FDA) to clear both Roche's multiple sclerosis (MS) treatment Ocrevus and Sanofi's new eczema drug Dupixent.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||44.67 - 45.13|
|52 Week Range||36.81 - 45.13|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.11|
|Dividend & Yield||1.58 (3.56%)|
|1y Target Est||N/A|